Absolutely no mention of AstraZeneca, at all. Another disappearing partner perhaps (this time significant). What happened to the Development and Option Agreement with AZ? Shareholders deserve much better. Hello ASIC!!
I’ve been adamant for years that DEP-Docetaxel is a commercial dud and going nowhere. My position is now only strengthened by the fact that DEP-Docetaxel was not accepted for presentation at ASCO in June.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-8
-
- There are more pages in this discussion • 46 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.29M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $12.03K | 116.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 109616 | 3 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |